Marriage Counselors in Junction City, KS Accepting Medicare

7 Marriage Counselors found. Showing 1 - 7

Mrs. Angela Lynne Howard, LMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 1407 Saint Marys Rd, Junction City, KS 66441 Phone: 785-762-7161

Allison Fulmore, LMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 1421 Meadowbrooke Ln, Junction City, KS 66441 Phone: 316-249-3066

Mr. John Warren Norton, MA,MS,LCMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 126 Parkside Cir, Junction City, KS 66441 Phone: 785-762-2504    Fax: 785-762-2504

Julia Romo-figueroa Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 814 Caroline Ave, Junction City, KS 66441 Phone: 785-762-5250

Bj Edward Solander, LMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 929 South Washington Street, Junction City, KS 66441 Phone: 785-390-1599

Sarah Anne Mcmillen, M.S. Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 814 Caroline Ave, Junction City, KS 66441 Phone: 785-762-5250    Fax: 785-762-2144

Dr. Lorrie Lea Gfeller, PH.D., LCMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 132 N Eisenhower Dr, Junction City, KS 66441 Phone: 785-762-4210    Fax: 785-762-6876

News Archive

Online mobile phone app for users of CME Medical's T34 Ambulatory Syringe Pump

CME Medical, the UK's fastest growing specialist infusion company, has launched a new online mobile phone app for users of the company's T34TM Ambulatory Syringe Pump . The app demonstrates the company's commitment to developing accessible education programmes for all of its customers. It incorporates information which is also available in printed Quick User Guides and helps people through the process of using the pump. The app can be used on any device with an internet connection.

FDA assigns PDUFA action date for Orexigen's Contrave NDA review

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that the U.S. Food and Drug Administration has assigned a Prescription Drug User Fee Act (PDUFA) action date of January 31, 2011 for the review of the Contrave® (naltrexone sustained release (SR)/bupropion SR) New Drug Application (NDA).

Study finds that physicians help patients quit smoking but could provide more education

Physicians are an important resource in New Jerseyans' fight to stop smoking, but they can and should become even more effective educators, according to a survey by the Center for State Health Policy (CSHP) at Rutgers, The State University of New Jersey.

Researchers examine models for automatic bone age estimation

Ensembles created using models submitted to the RSNA Pediatric Bone Age Machine Learning Challenge convincingly outperformed single-model prediction of bone age, according to a study published in the journal Radiology: Artificial Intelligence.

New understanding of breast cancer metastasis to bone

In breast cancer patients with metastatic disease, bone is the most common site of metastasis and the most common site of first distant relapse, with roughly half (48%) of breast cancer patients developing bone metastases after treatment.

Read more Medical News

› Verified 1 days ago